A 10-month-old boy named KJ Muldoon has become the first person to receive a customized CRISPR therapy aimed at correcting a specific genetic mutation that obstructed his protein processing. Recent assessments indicate marked improvement in his health, although pediatrician Rebecca Ahrens-Nicklas advises caution in labeling his condition as cured at this early stage. Beyond this breakthrough, the FDA has announced plans to reduce reliance on animal toxicity testing, reflecting a shift in regulatory practices. Meanwhile, scientists are experimenting with portable antimatter containment systems, marking significant advancements in multiple scientific fields.
KJ Muldoon is the first known individual to receive a personalized CRISPR therapy designed to specifically target his genetic mutation, showing promising health outcomes.
Although KJ appears healthy now after the CRISPR treatment, experts like Dr. Rebecca Ahrens-Nicklas suggest it's too early to define it as a cure.
Collection
[
|
...
]